Cantor Fitzgerald Reiterates Hold Rating, $37 PT for Endo Health Solutions

In a report published earlier today, Cantor Fitzgerald L.P. reiterated its Hold rating and $37.00 price target for Endo Health Solutions Inc.

. Cantor Fitzgerald went on to say “We believe a generic filer on Opana ER could cap share price rebound. ENDP has dropped following the Lidoderm settlement. While the stock looks attractive at these levels, we remain cautious ahead of an imminent ANDA filing on Opana ER, which we believe could create a new overhang on the stock. There is currently no Reference Listed Drug (RLD) for the new Opana ER formulation in the Orange Book (which bars a generic filing), and a Citizen Petition has been filed on 3/23/12 requesting that the FDA designate one. We believe that once an RLD is identified, a generic filer will promptly emerge.” Endo Health Solutions Inc. closed yesterday at $29.03.